

Yan Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1885316/publications.pdf>

Version: 2024-02-01

100
papers

2,195
citations

304743

22
h-index

289244

40
g-index

103
all docs

103
docs citations

103
times ranked

2614
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure of the μ -opioid receptor-Gi protein complex. <i>Nature</i> , 2018, 558, 547-552.	27.8	527
2	Huperzine A as Potential Treatment of Alzheimer's Disease: An Assessment on Chemistry, Pharmacology, and Clinical Studies. <i>Chemistry and Biodiversity</i> , 2011, 8, 1189-1204.	2.1	108
3	Design, Synthesis, and Biological Evaluation of 6β - and 6α -N-Heterocyclic Substituted Naltrexamine Derivatives as μ Opioid Receptor Selective Antagonists. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1416-1427.	6.4	70
4	Total Synthesis of Anibamine, a Novel Natural Product as a Chemokine Receptor CCR5 Antagonist. <i>Organic Letters</i> , 2007, 9, 2043-2046.	4.6	62
5	Homology Modeling and Molecular Dynamics Simulations of the Mu Opioid Receptor in a Membrane-Aqueous System. <i>ChemBioChem</i> , 2005, 6, 853-859.	2.6	46
6	Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4627-4630.	2.2	39
7	Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease. <i>Molecular Pharmaceutics</i> , 2017, 14, 3499-3511.	4.6	39
8	Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. <i>Neuropharmacology</i> , 2019, 150, 200-209.	4.1	37
9	A bivalent ligand targeting the putative mu opioid receptor and chemokine receptor CCR5 heterodimer: binding affinity versus functional activities. <i>MedChemComm</i> , 2013, 4, 847.	3.4	36
10	Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 2633.	2.8	35
11	Design, Synthesis, and Biological Evaluation of 14-Heteroaromatic-Substituted Naltrexone Derivatives: Pharmacological Profile Switch from Mu Opioid Receptor Selectivity to Mu/Kappa Opioid Receptor Dual Selectivity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9156-9169.	6.4	35
12	Comparative Docking Study of Anibamine as the First Natural Product CCR5 Antagonist in CCR5 Homology Models. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 120-132.	5.4	34
13	Characterization of 6β - and 6α -N-Heterocyclic Substituted Naltrexamine Derivatives as Novel Leads to Development of Mu Opioid Receptor Selective Antagonists. <i>ACS Chemical Neuroscience</i> , 2011, 2, 346-351.	3.5	33
14	Design of bivalent ligands targeting putative GPCR dimers. <i>Drug Discovery Today</i> , 2021, 26, 189-199.	6.4	33
15	A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5- μ -opioid receptor interactions between human astroglia and microglia. <i>Aids</i> , 2013, 27, 2181-2190.	2.2	31
16	Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5969-5987.	3.0	31
17	Antinociceptive Interactions between the Imidazoline I2 Receptor Agonist 2-BFI and Opioids in Rats: Role of Efficacy at the μ -Opioid Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 357, 509-519.	2.5	30
18	G Protein-Coupled Estrogen Receptor (GPER) Agonist Dual Binding Mode Analyses Toward Understanding of Its Activation Mechanism: A Comparative Homology Modeling Approach. <i>Molecular Informatics</i> , 2013, 32, 647-658.	2.5	28

#	ARTICLE	IF	CITATIONS
19	Structure-Activity Relationship Studies of μ - and δ -Indolylacetamidonealtrexamine Derivatives as Bitopic μ Opioid Receptor Modulators and Elaboration of the "Message-Address" Concept To Comprehend Their Functional Conversion. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1075-1090.	3.5	28
20	Teaching an old dog new tricks: Drug discovery by repositioning natural products and their derivatives. <i>Drug Discovery Today</i> , 2022, 27, 1936-1944.	6.4	28
21	Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2530-2538.	3.0	26
22	A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55. <i>Journal of Molecular Graphics and Modelling</i> , 2013, 39, 50-60.	2.4	24
23	Application of Receptor Theory to the Design and Use of Fixed-Proportion μ -Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 37-47.	2.5	24
24	Design, Synthesis, and Biological Evaluation of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(4-pyridyl)carboxamido]morphinan Derivatives as Peripheral Selective μ Opioid Receptor Agents. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10118-10129.	6.4	22
25	Preclinical Disposition (In Vitro) of Novel μ -Opioid Receptor Selective Antagonists. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1589-1596.	3.3	21
26	δ -N-Heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral μ opioid receptor selective antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4731-4734.	2.2	21
27	Binding mode characterization of μ - and δ -N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: Application of the "message-address" concept in development of μ opioid receptor selective antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6405-6413.	3.0	20
28	Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1055-1065.	3.5	20
29	14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide μ opioid receptor selective antagonists: Design, synthesis, and biological studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1825-1829.	2.2	19
30	Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-(isoquinoline-3-carboxamido)morphinan analogues as opioid receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1701-1715.	3.0	19
31	CRIP1a inhibits endocytosis of G-protein coupled receptors activated by endocannabinoids and glutamate by a common molecular mechanism. <i>Journal of Neurochemistry</i> , 2017, 141, 577-591.	3.9	19
32	Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2012, 55, 395-408.	5.5	18
33	Effects of the novel, selective and low-efficacy μ opioid receptor ligand NAQ on intracranial self-stimulation in rats. <i>Psychopharmacology</i> , 2015, 232, 815-824.	3.1	18
34	San-Huang-Xie-Xin-Tang Constituents Exert Drug-Drug Interaction of Mutual Reinforcement at Both Pharmacodynamics and Pharmacokinetic Level: A Review. <i>Frontiers in Pharmacology</i> , 2016, 7, 448.	3.5	18
35	The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5093-5097.	2.2	17
36	5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC): A novel non-nitrogenous ligand for 5-HT _{2B} receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1489-1492.	2.2	17

#	ARTICLE	IF	CITATIONS
37	Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2319-2323.	2.2	17
38	Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2518-2532.	3.5	17
39	Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(4-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ / κ Opioid Receptor Dual Selective Ligands. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 561-574.	6.4	17
40	Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between <i>in Vitro</i> Agonist Bias and <i>in Vivo</i> Pharmacological Effects. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3036-3050.	3.5	17
41	Regio- and Stereoselective Syntheses of the Natural Product CCR5 Antagonist Anibamine and its Three Olefin Isomers. <i>Journal of Organic Chemistry</i> , 2011, 76, 7945-7952.	3.2	16
42	Bivalent Ligands Targeting Chemokine Receptor Dimerization: Molecular Design and Functional Studies. <i>Current Topics in Medicinal Chemistry</i> , 2014, 14, 1606-1618.	2.1	16
43	Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(4-pyridyl)carboxamido]morphinan derivatives toward the development of the μ opioid receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5625-5629.	2.2	15
44	The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5159-5163.	2.2	15
45	In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy μ opioid receptor modulator. <i>European Journal of Pharmacology</i> , 2018, 827, 32-40.	3.5	15
46	Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation. <i>Acta Crystallographica Section D: Structural Biology</i> , 2018, 74, 956-964.	2.3	15
47	17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-(4-pyridylcarboxamido)morphinan (NAP) Modulating the μ Opioid Receptor in a Biased Fashion. <i>ACS Chemical Neuroscience</i> , 2016, 7, 297-304.	3.5	14
48	VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions. <i>Scientific Reports</i> , 2020, 10, 20277.	3.3	14
49	Structural elucidation and in vivo anti-arthritis activity of β -amyryn and polypunonic acid isolated from the root bark of <i>Ziziphys abyssinica</i> Hochst. <i>Ex. A Rich</i> (Rhamnaceae). <i>Bioorganic Chemistry</i> , 2020, 98, 103744.	4.1	14
50	Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2378-2392.	2.1	14
51	Structure activity relationship studies of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-(isoquinoline-3-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: Preliminary results on the role of electronic characteristics for affinity and function. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5045-5048.	2.2	13
52	Predicting the molecular interactions of CRIP1a—cannabinoid 1 receptor with integrated molecular modeling approaches. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1158-1165.	2.2	13
53	Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. <i>Drug Discovery Today</i> , 2020, 25, 1682-1692.	6.4	13
54	IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 191-202.	4.1	13

#	ARTICLE	IF	CITATIONS
55	Identification of Small-Molecule Inhibitors against Meso-2, 6-Diaminopimelate Dehydrogenase from <i>Porphyromonas gingivalis</i> . <i>PLoS ONE</i> , 2015, 10, e0141126.	2.5	13
56	Drug discovery efforts toward inhibitors of canonical Wnt/ β -catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010–2020). <i>Drug Discovery Today</i> , 2022, 27, 1115-1127.	6.4	13
57	Toward the three-dimensional structure and lysophosphatidic acid binding characteristics of the LPA4/p2y9/GPR23 receptor: A homology modeling study. <i>Journal of Molecular Graphics and Modelling</i> , 2009, 28, 70-79.	2.4	12
58	Synthesis and Characterization of 5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC) and Its Analogues as Non-nitrogenous 5-HT _{2B} Ligands. <i>Journal of Natural Products</i> , 2015, 78, 1859-1867.	3.0	12
59	6 β -N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1120-1129.	3.5	12
60	Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 11399-11415.	6.4	12
61	Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2013, 69, 647-658.	5.5	11
62	Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14 β -dihydroxy-4,5 β -epoxy-6 β -(isoquinoline-3-carboxamido)morphinan (NAQ) as a μ opioid receptor selective ligand. <i>European Journal of Pharmacology</i> , 2014, 736, 124-130.	3.5	11
63	Small molecule inhibits activity of scavenger receptor A: Lead identification and preliminary studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3179-3183.	2.2	11
64	Binding mode analyses of NAP derivatives as μ opioid receptor selective ligands through docking studies and molecular dynamics simulation. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 2463-2471.	3.0	11
65	An efficient procedure for the preparation of natural products bearing the 2-(2-phenylethyl)chromone skeleton. <i>Tetrahedron Letters</i> , 2013, 54, 4292-4295.	1.4	10
66	Computational insights into the molecular mechanisms of differentiated allosteric modulation at the μ opioid receptor by structurally similar bitopic modulators. <i>Journal of Computer-Aided Molecular Design</i> , 2020, 34, 879-895.	2.9	9
67	Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property. <i>Expert Opinion on Therapeutic Patents</i> , 2022, 32, 115-130.	5.0	9
68	Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3721-3725.	2.2	8
69	Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7702-7723.	6.4	8
70	Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3719-3722.	2.2	7
71	Understanding the role of glucose regulated protein 170 (GRP170) as a nucleotide exchange factor through molecular simulations. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 85, 160-170.	2.4	7
72	Role of μ -opioid agonist efficacy on antinociceptive interactions between μ agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys. <i>European Journal of Pharmacology</i> , 2019, 844, 175-182.	3.5	7

#	ARTICLE	IF	CITATIONS
73	Anibamine and Its Analogues: Potent Antiplasmodial Agents from <i>Aniba citrifolia</i> . <i>Journal of Natural Products</i> , 2020, 83, 569-577.	3.0	7
74	Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14724-14739.	6.4	7
75	Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2318-2324.	2.8	7
76	Stereoselective synthesis of the two major metabolites of spironolactone, 3 β - and 3 β -hydroxy-7 α -methylthio-17 β -pregn-4-ene-21,17-carbolactone. <i>Steroids</i> , 2007, 72, 569-572.	1.8	6
77	Diaminopimelic acid (DAP) analogs bearing isoxazoline moiety as selective inhibitors against meso-diaminopimelate dehydrogenase (m-Ddh) from <i>Porphyromonas gingivalis</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3840-3844.	2.2	6
78	Methylation Products of 6 β -N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators. <i>ACS Chemical Neuroscience</i> , 2018, 9, 3028-3037.	3.5	6
79	Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer. <i>RSC Medicinal Chemistry</i> , 2020, 11, 125-131.	3.9	6
80	Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5095-5112.	6.4	6
81	Facile synthesis of 2,3,5,6-tetrabromo-4-methyl-nitrocyclohexa-2,5-dien-1-one, a mild nitration reagent. <i>Tetrahedron Letters</i> , 2012, 53, 1592-1594.	1.4	5
82	Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT _{2B} receptor antagonist scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127511.	2.2	5
83	Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5 α -epoxy-3,14 β -dihydroxy-6 β -[(4 β -pyridyl)carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors. <i>Bioorganic Chemistry</i> , 2021, 109, 104702.	4.1	5
84	Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimers. <i>Bioorganic Chemistry</i> , 2022, 120, 105641.	4.1	5
85	Understanding molecular interactions between scavenger receptor A and its natural product inhibitors through molecular modeling studies. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 77, 189-199.	2.4	4
86	Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators. <i>Future Medicinal Chemistry</i> , 2021, 13, 551-573.	2.3	4
87	Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease. <i>Pharmaceutics</i> , 2021, 13, 1148.	4.5	4
88	Exploration of naphthoquinone analogs in targeting the TCF-DNA interaction to inhibit the Wnt/ β -catenin signaling pathway. <i>Bioorganic Chemistry</i> , 2022, 124, 105812.	4.1	4
89	Nanoconjugated NAP as a Potent and Periphery Selective Mu Opioid Receptor Modulator To Treat Opioid-Induced Constipation. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 78-83.	2.8	3
90	Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 72-76.	2.2	3

#	ARTICLE	IF	CITATIONS
91	Exploring the binding mechanisms of diaminopimelic acid analogs to meso-diaminopimelate dehydrogenase by molecular modeling. <i>Journal of Molecular Graphics and Modelling</i> , 2018, 83, 100-111.	2.4	3
92	Development of structure-based pharmacophore to target the β -catenin-TCF protein-protein interaction. <i>Medicinal Chemistry Research</i> , 2021, 30, 429-439.	2.4	3
93	Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation Treatment. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4991-5003.	6.4	3
94	Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3-fluoro-4-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder. <i>European Journal of Pharmacology</i> , 2019, 865, 172812.	3.5	2
95	Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 41, 127953.	2.2	2
96	Novel Structurally-Modified Allosteric Effectors of Hemoglobin Exhibit Superior Antisickling Properties. <i>Blood</i> , 2014, 124, 218-218.	1.4	2
97	Stereoselective syntheses of 3-dehydroxynaltrexamines and N-methyl-3-dehydroxynaltrexamines. <i>Tetrahedron Letters</i> , 2020, 61, 152379.	1.4	1
98	Effective and Versatile Synthesis of Ginkgotoxin and Its 4-O-Derivatives through Regioselective 4-O-Alkylation and 4-O-Chlorination of 3,5-O-Dibenzylpyridoxine. <i>SynOpen</i> , 2020, 04, 51-54.	1.7	1
99	Agonist-Promoted Phosphorylation and Internalization of the Kappa Opioid Receptor in Mouse Brains: Lack of Connection With Conditioned Place Aversion. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	1
100	Elucidating the binding mechanism of LPA species and analogs in an LPA4 receptor homology model. <i>Journal of Molecular Graphics and Modelling</i> , 2022, , 108274.	2.4	0